WASHINGTON (Reuters) - U.S. Democratic lawmakers seeking to bolster Food and Drug Administration oversight of imported products took aim at medical devices and cosmetics on Wednesday, saying the agency lacks the money and power to properly regulate them.
The FDA is especially squeezed as the United States imports a growing number of catheters, heart devices, soaps, shampoos and other items, members of a U.S. House of Representatives Energy and Commerce panel said at a hearing.
"While the market for these products becomes increasingly global, the FDA has no requirement to inspect foreign establishments manufacturing medical devices," said Rep. Frank Pallone, a New Jersey Democrat who led the panel.
The FDA inspects foreign makers of heart defibrillators and other so-called high risk devices every six years on average, while makers of hearing aids and other less risky devices are checked an average of every 27 years, according to the Government Accountability Office.
Device facilities in the United States are inspected an average of every three to five years, the GAO said.
Wednesday's hearing comes as lawmakers consider sweeping legislation that calls for drug and device makers, food manufacturers and cosmetic companies to register with the FDA and pay for mandatory inspections of foreign factories.
The proposed bill comes after a rash of tainted goods imported from China, including pet food, toothpaste and the blood-thinning drug heparin.
While both Democrats and Republicans generally support efforts to empower the agency, several Republicans likened industry fees to an added tax that would burden manufacturers.
Rep. Joe Barton, a Texas Republican, also said imported devices did not pose the same risks as other products.
"We've had major problems with food imports from China, we've had major problems with drug imports from China, but I'm not aware that we've had major problems with medical device imports from China," he said.
Representatives for device makers said more oversight was unnecessary. Greater inspections for less risky products, such as contact lenses and glucose meters, would keep products from getting to patients quickly, they said.
